Reasoning Engine

Conducting research…

Step 1 / 5
  1. Discovering sources
    Identified 6 candidate sources across 3 publication types.
  2. Analyzing sources
    Extracted atomic claims; scored credibility, recency, and bias on each.
  3. Cross-referencing
    Detected contradictions and reconciled overlapping claims.
  4. Synthesizing findings
    Compressed claim graph into structural themes and a working thesis.
  5. Generating intelligence
    Drafted executive brief, evidence map, risks, and recommendations.

Research Telemetry

live · demo
Reasoning
80/100
Confidence
76/100
Evidence
84/100
Depth
78/100
Diversity
84/100

Synthesized Answer

Build longevity investment thesis with bet sizing

Longevity investment thesis: core 60% in GLP-1 and metabolic compounders (Lilly, NovoNordisk), satellite 25% in disease-specific longevity-adjacent (senolytics, mTOR, autophagy), exploratory 15% in platforms (Altos, Retro, NewLimit) with multi-year capital commitment.

Key Points

  • Core 60%: Lilly + NovoNordisk metabolic compounders
  • Satellite 25%: disease-specific senolytic, mTOR, autophagy
  • Exploratory 15%: platforms (Altos, Retro, NewLimit), venture-style
  • Bet on indication-disciplined programs, not 'longevity' branding
  • Catalysts: EVOKE, retatrutide, Unity DME, partial reprogramming FIH

Knowledge Graph

11 nodes · 12 edges
topicconceptcompanyentity
Longevity biotechGLP-1 receptor agonistsSenolyticsCellular reprogrammingHallmarks of AgingAltos LabsRetro BiosciencesUnity BiotechnologyBioAgeLoyal (canine)FDA pathway

Auto-generated Insights

Trend

GLP-1 receptor agonists are demonstrating longevity-adjacent benefits at scale.

Finding

Partial cellular reprogramming has cleared the tumorigenesis bar in mouse studies.

Signal

FDA acceptance of Loyal's canine longevity application opens regulatory pathway precedent.

Contradiction

Retail longevity-supplement market booms without clinical evidence base.

Structured Data

Extracted from sources

Cumulative longevity biotech capital

$11B

$3B YoY

disclosed, all-time

GLP-1 MACE risk reduction (SELECT)

−20%

vs placebo

non-diabetic, CV disease

Clinical-stage company concentration

70%

of capital in 8 cos.

Endpoints

Hallmarks of Aging (current)

12

vs 9 in 2013

Cell, Lopez-Otin et al.

Sources6 ranked

Sorted by relevance
C
cell.com·this week
Research Paper

Hallmarks of Aging: Updated 2023 Framework

Lopez-Otin et al. expand original hallmarks framework to 12 interconnected aging mechanisms, providing organizing structure for intervention research.

Cred
98
Auth
98
Fresh
76
Rel
88
●Center
Strongevidence
N
nejm.org·this week
Research Paper

Semaglutide and Cardiovascular Outcomes in Non-Diabetic Patients

SELECT trial: semaglutide reduced major adverse cardiovascular events by 20% in overweight, non-diabetic patients with existing CV disease.

Cred
98
Auth
98
Fresh
84
Rel
88
●Center
Strongevidence
N
nature.com·this week
Research Paper

Altos Labs and Retro Biosciences Pipeline Update

Both companies focus on partial cellular reprogramming via Yamanaka factors; recent mouse studies show tissue rejuvenation without tumorigenesis.

Cred
97
Auth
96
Fresh
88
Rel
88
●Center
Strongevidence
B
biocentury.com·this week
Article

Senolytics Clinical Progress: Unity, BioAge, Cleara

Unity's UBX1325 advanced to Phase III for diabetic macular edema; BioAge's azelaprag in Phase II for obesity-related muscle loss.

Cred
86
Auth
85
Fresh
91
Rel
88
●Center
Strongevidence
F
fda.gov·this week
News

Loyal and the Canine Aging Translation Pathway

FDA's Center for Veterinary Medicine has accepted Loyal's pharmaceutical for evaluation of reasonable expectation of effectiveness for canine lifespan extension.

Cred
97
Auth
98
Fresh
88
Rel
88
●Center
Strongevidence
E
endpoints.com·this week
Article

Longevity Biotech Funding Landscape 2026

Total disclosed longevity-biotech capital reached $11B cumulative; ~70% concentrated in 8 companies. Retail-product market remains evidence-light.

Cred
88
Auth
85
Fresh
94
Rel
88
●Center
Strongevidence

Refine your research

Map GLP-1 longevity-adjacent trial pipelineCompare senolytic clinical programsProject cellular reprogramming timelineIdentify regulatory pathway scenariosBuild longevity investment thesis with bet sizingGenerate executive summary

Demo mode · All sources, insights, and data are mock-generated for illustration.